OBX vs BRAI Comparison

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.